Skip to content
Invenirex
About us
InvenireX: Next-Generation Digital PCR
InvenireX is developing a next-generation platform for researchers who need confidence in low-level DNA and RNA measurement without the complexity and cost associated with other digital PCR approaches.
Our R.O.S.A.L.I.N.D. platform is designed to deliver the key benefit researchers value from digital PCR: absolute quantification of nucleic-acid targets. Rather than relying on amplification curves and standard curves, the technology is built to enable direct digital measurement of target molecules, supporting more confident decisions when concentrations are low and small differences matter.
Why visit our stand?
Come and see how InvenireX is aiming to make high-sensitivity molecular quantification more accessible. If your current qPCR or dPCR workflow involves costly and lengthy run times, multiple preparation steps, specialist equipment, complex data interpretation or repeat testing at the limit of detection, we would like to talk.
On our stand, you can explore:
1. A fresh approach to absolute DNA and RNA quantification
2. A streamlined workflow designed to reduce reliance on thermal cycling and conventional amplification steps
3. How digital measurement could support difficult low-copy-number applications
4. Opportunities to collaborate on assays, pilot studies and early-access evaluations
This is not simply another PCR instrument. It is a platform being developed to help laboratories obtain clearer molecular answers with a workflow designed around speed, simplicity and confidence.
Who is it for?
InvenireX is for organisations where accurate nucleic-acid quantification is critical, particularly when target molecules are present at very low abundance. Potential users include:
1. Biotech and pharma R&D teams developing cell and gene therapies, precision medicines, companion diagnostics or molecular assays
2. Academic and translational researchers working in genomics, cancer biology, infectious disease, biomarker discovery and molecular medicine
3. Core facilities and genomics laboratories seeking to offer advanced quantification capability without adding unnecessary workflow complexity
4. Molecular diagnostic developers exploring future-generation approaches to highly sensitive pathogen or biomarker detection
5. Public-health, environmental, veterinary and food-testing laboratories that need sensitive detection and quantification of low-level targets
6. Liquid-biopsy and oncology researchers monitoring rare variants, circulating nucleic acids or minimal residual disease
7. Gene-therapy and bioprocess teams needing accurate measurement of vector genomes, residual DNA or other critical molecular targets
What are we offering?
InvenireX offers a developing platform for digital, absolute nucleic-acid quantification based on programmable target recognition, microchip-based measurement and automated fluorescence analysis. The platform is being designed to provide:
1. Absolute quantification: A direct digital readout intended to reduce dependence on qPCR curves.
2. High analytical sensitivity: A technology approach intended for scarce and low-abundance DNA or RNA targets.
3. Automation-friendly analysis: Instrument software designed to support automated signal identification and quantification.
4. Assay flexibility: your standard qPCR Taqman PCR reagents are compatable with our device.
Speak to us:
Visit the InvenireX stand to discuss your current qPCR or dPCR bottleneck, see the technology concept and explore whether an early collaboration, assay feasibility study or pilot evaluation could support your work.
If your science depends on measuring the molecules others miss, InvenireX wants to help you count them with confidence.
